Tech Company Financing Transactions
Peptimmune Funding Round
Covera Ventures, MPM Capital and New Enterprise Associates participated in a $8.9 million Series D funding round for Peptimmune. The round was announced on 7/16/2008.
Transaction Overview
Company Name
Announced On
7/16/2008
Transaction Type
Venture Equity
Amount
$8,900,000
Round
Series D
Investors
Proceeds Purpose
The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
64 Sidney Street 380
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Fredric Price
Chief Executive Officer
Thomas Mathers
VP - R & D
Eric Zanelli
VP - Regulatory Affairs
Uday Patel
Browse more venture capital transactions:
Prev: 7/16/2008: BestOfMedia venture capital transaction
Next: 7/16/2008: Sojern venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs